Bruce P. Connop
Director/Board Member at IBEX TECHNOLOGIES
Bruce P. Connop active positions
| Companies | Position | Start | End |
|---|---|---|---|
| IBEX TECHNOLOGIES | Director/Board Member | 10/10/2017 | - |
| Independent Dir/Board Member | 10/10/2017 | - | |
Active Pass Pharmaceuticals, Inc.
 Active Pass Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Active Pass Pharmaceuticals, Inc. develops drugs for infectious diseases. It engages in the development of drugs that inhibit ABC transporters. The firm also provides portfolio of therapeutic programs, including age-related macular degeneration, travelers' diarrhea, and lipid disorders. The company was founded by Peter B Reiner in 1998 and is headquartered in Vancouver, Canada. | Chief Tech/Sci/R&D Officer | 31/12/1998 | - |
Career history of Bruce P. Connop
Former positions of Bruce P. Connop
| Companies | Position | Start | End |
|---|---|---|---|
| TRANSITION THERAPEUTICS INC | Corporate Officer/Principal | 30/11/2006 | - |
Training of Bruce P. Connop
| Queen's University | Doctorate Degree |
Statistics
International
| Canada | 5 |
Operational
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
| Corporate Officer/Principal | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 3 |
|---|---|
Active Pass Pharmaceuticals, Inc.
Active Pass Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Active Pass Pharmaceuticals, Inc. develops drugs for infectious diseases. It engages in the development of drugs that inhibit ABC transporters. The firm also provides portfolio of therapeutic programs, including age-related macular degeneration, travelers' diarrhea, and lipid disorders. The company was founded by Peter B Reiner in 1998 and is headquartered in Vancouver, Canada. | Health Technology |
Transition Therapeutics, Inc.
 Transition Therapeutics, Inc. Medical SpecialtiesHealth Technology Transition Therapeutics, Inc. develops novel therapeutics for disease indications. It operates through research and development of therapeutic agents segment. The firm's products include ELND005 for the treatment of alzheimer's disease, bipolar disorder and down syndrome. Its metabolic drug candidate is TT401 for treatment of type 2 diabetes and accompanying obesity. Transition Therapeutics was founded by Tony F. Cruz on July 6, 1998 and is headquartered in Toronto, Canada. | Health Technology |
IBEX Technologies, Inc.
 IBEX Technologies, Inc. Medical SpecialtiesHealth Technology IBEX Technologies, Inc. manufactures and markets enzymes for biomedical use. The firm also specializes in the custom aliquoting, filling, and lyophilization of enzymes in diagnostic disposables for medical devices. Its products include glycobiology enzymes from flavobacterium heparinum, collagen assays, collagen antibodies, and diamine oxidase liquid. The company was founded by Robert A. Heft on April 10, 1972 and is headquartered in Montréal, Canada. | Health Technology |
- Stock Market
- Insiders
- Bruce P. Connop
- Experience
